Gatorade Gets A 'Lyte' Overhaul and Laird Goes On A Buying Spree

The latest CPG week shows Gatorade entering a "transformational new era" as PepsiCo rolls out its Advanced Hydration System. By bundling Thirst Quencher, Zero, Lower Sugar under a "Hydrates Better" banner and introducing Gatorlite Longer Lasting for 2027, the brand aims at the 150 million Americans who experience mild or moderate dehydration each week. This pivot moves Gatorade beyond elite‑athlete branding toward everyday wellness. At the same earnings call, PepsiCo highlighted an 8.5 % revenue rise driven by price‑adjusted growth and a $2 billion‑plus better‑for‑you snack portfolio featuring protein‑rich Sun Chips, Siete and Quaker rice cakes.

Laird Superfood’s aggressive expansion continued with a $48 million purchase of vertically integrated Terasol Superfoods, funded by a $60 million Nexus Capital private placement that now owns 71 % of the company. The deal adds superfood‑based snack mixes, protein bites and baking ingredients to Laird’s existing coffee creamers, adaptogenic powders and hydration formulas. While the acquisition promises a broader wellness platform, analysts warn that repeated vertical‑integration moves echo the brand’s 2021‑22 struggles after the failed Picky Bars purchase and costly Oregon plant closure. Nonetheless, Q4 sales rose 15 % and adjusted EBITDA improved, suggesting the growth‑by‑acquisition model may be regaining traction.

Meanwhile, GLP‑1 medications such as Ozempic and Wegovy are reshaping grocery habits, pushing consumers toward high‑protein, high‑fiber, low‑sugar options and even influencing beauty and personal‑care expectations. Acosta’s research shows over 12 % of Americans have tried a GLP‑1 drug, prompting brands to launch ingestible‑beauty products like probiotic coleslaw and collagen‑infused granola. At the same time, pending federal legislation to let states opt out of the November hemp‑derived THC ban is prompting companies such as Drink Hippie to retire THC‑based beverages and double‑down on non‑intoxicating energy drinks. These regulatory and health‑trend dynamics underscore a rapid shift toward functional, outcome‑focused CPG portfolios.